Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 3/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 7/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11389921 | 0.91 | LMNA (0.57) | ADORA2BRXFP1ALDH1A1LMNAGAA | |
| SCHEMBL25295543 | 0.88 | LMNA (0.56) | ADORA2BRXFP1LMNAGAAMAPK1 | |
| SCHEMBL30563571 | 0.88 | LMNA (0.56) | ADORA2BRXFP1LMNAGAAMAPK1 | |
| SCHEMBL30563533 | 0.87 | LMNA (0.56) | ADORA2BRXFP1ALDH1A1LMNAGAA | |
| SCHEMBL25292741 | 0.87 | LMNA (0.56) | ADORA2BRXFP1ALDH1A1LMNAGAA | |
| SCHEMBL25248642 | 0.86 | LMNA (0.54) | ADORA2BRXFP1ALDH1A1LMNAGAA | |
| SCHEMBL30563556 | 0.86 | LMNA (0.54) | ADORA2BRXFP1ALDH1A1LMNAGAA | |
| SCHEMBL10970100 | 0.85 | LMNA (0.64) | ADORA2BRXFP1ALDH1A1LMNAGAA | |
| SCHEMBL25248797 | 0.85 | LMNA (0.49) | ADORA2BRXFP1ALDH1A1LMNAGAA | |
| SCHEMBL30563550 | 0.85 | LMNA (0.49) | ADORA2BRXFP1ALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1079650-A | The new purposes of nicotinic acid and derivant thereof | QIU BOLING (CN) | 1993-12-22 | — | — | CN | claimed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250066413-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | METRO INTERNATIONAL BIOTECH, LLC | 2025-02-27 | — | — | US | disclosed |
| EP-4452279-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | Metro International Biotech, LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-118541157-A | Composition for treating inflammation | 麦德龙国际生物科技有限责任公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-117805308-A | Processing method of chromatographic off-machine data and related application thereof | 四川帕诺米克生物科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11878994-B1 | Compositions for treatment of inflammation | METRO INTERNATIONAL BIOTECH, LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20110171195-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | DUKE UNIVERSITY (US) | 2011-07-14 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100239667-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | EGALET A/S (DK) | 2010-09-23 | — | — | US | disclosed |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2155167-A2 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | Egalet A/S (DK) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008157205-A2 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | DUKE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008148798-A2 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | EGALET A/S (DK) | 2008-12-11 | — | — | WO | disclosed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | disclosed |
| EP-0532446-A1 | Use of xanthines in the treatment or prevention of hypeoglycemia | NOVO NORDISK A/S (DK) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | ADORA2B 3900/4885RXFP1 3046/4885ALDH1A1 2174/4885 |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | ADORA2B 648/4885RXFP1 2437/4885ALDH1A1 2656/4885 |
| US-20110171195-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | PDE7A, PDE8A, PDE8B | ADORA2B 1024/4885RXFP1 1782/4885ALDH1A1 1738/4885 |
| US-20250066413-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | NQO1, NAMPT, MPO | ADORA2B 1104/4885RXFP1 2201/4885ALDH1A1 642/4885 |
| US-11878994-B1 | Compositions for treatment of inflammation | NQO1, NAMPT, MPO | ADORA2B 1104/4885RXFP1 2201/4885ALDH1A1 642/4885 |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | PNPO, NAMPT, NAPRT | ADORA2B 1559/4885RXFP1 4520/4885ALDH1A1 1385/4885 |
| US-20100239667-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | SI, GIPR, MLN | ADORA2B 820/4885RXFP1 685/4885ALDH1A1 3424/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | ADORA2B 3962/4885RXFP1 2975/4885ALDH1A1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.